Compare METC & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | METC | MDXG |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | United States |
| Employees | 900 | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | N/A | 2007 |
| Metric | METC | MDXG |
|---|---|---|
| Price | $13.55 | $3.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $33.88 | $10.00 |
| AVG Volume (30 Days) | ★ 1.9M | 961.3K |
| Earning Date | 05-11-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | N/A | ★ 0.32 |
| Revenue | N/A | ★ $418,630,000.00 |
| Revenue This Year | $18.50 | N/A |
| Revenue Next Year | $12.27 | $13.02 |
| P/E Ratio | ★ N/A | $12.59 |
| Revenue Growth | N/A | ★ 19.99 |
| 52 Week Low | $8.26 | $3.77 |
| 52 Week High | $57.80 | $7.99 |
| Indicator | METC | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 41.95 | 32.48 |
| Support Level | $13.45 | $3.77 |
| Resistance Level | $16.20 | $7.39 |
| Average True Range (ATR) | 1.14 | 0.15 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 12.54 | 16.51 |
Ramaco Resources Inc is a United States-based company that operates as a pure-play metallurgical coal company with operations in southern West Virginia and southwestern Virginia. Its portfolio includes high-quality metallurgical coal reserves & resources, with a focus on properties such as Elk Creek, Berwind, Knox Creek, and Maben. These properties are strategically located to serve North American blast furnace steel mills and coke plants, as well as international metallurgical coal consumers. Additionally, the company controls mineral deposits in Sheridan, Wyoming, exploring potential opportunities in rare earth elements and coal-to-carbon-based products. The company's two operating segments are Metallurgical Coal segment; and Rare Earths and Critical Minerals.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.